We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

235 hedge funds and large institutions have $2.67B invested in Amicus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 85 increasing their positions, 73 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

237% more call options, than puts

Call options by funds: $18.8M | Put options by funds: $5.59M

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

16% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 73

3% less capital invested

Capital invested by funds: $2.74B → $2.67B (-$68.9M)

1.98% less ownership

Funds ownership: 106.07%104.09% (-2%)

9% less funds holding

Funds holding: 259235 (-24)

41% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 54

Holders
235
Holders Change
-24
Holders Change %
-9.27%
% of All Funds
4.09%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
32
Increased
85
Reduced
73
Closed
54
Calls
$18.8M
Puts
$5.59M
Net Calls
+$13.2M
Net Calls Change
+$8.3M
Name Holding Trade Value Shares
Change
Change in
Stake
PM
51
Parametrica Management
Hong Kong
$6.69M +$841K +86,168 +14%
RHJA
52
Rice Hall James & Associates
California
$6.27M -$1.37M -140,747 -18%
Two Sigma Investments
53
Two Sigma Investments
New York
$6.07M -$16.8M -1,724,507 -73%
TCM
54
Tekla Capital Management
Massachusetts
$5.99M
PAM
55
Panagora Asset Management
Massachusetts
$5.82M +$3.01M +308,267 +104%
Wells Fargo
56
Wells Fargo
California
$5.09M -$1.37M -140,754 -21%
Citigroup
57
Citigroup
New York
$4.88M +$713K +73,010 +17%
BCM
58
Burrage Capital Management
Massachusetts
$4.82M +$4.88M +500,000 New
BC
59
Brookfield Corp
Ontario, Canada
$4.76M +$142K +14,500 +3%
IHAM
60
Integral Health Asset Management
New York
$4.58M +$4.64M +475,000 New
SEI Investments
61
SEI Investments
Pennsylvania
$4.54M +$226K +23,152 +5%
Swiss National Bank
62
Swiss National Bank
Switzerland
$4.49M -$681K -69,800 -13%
Russell Investments Group
63
Russell Investments Group
United Kingdom
$4.41M +$2.47M +253,009 +123%
SAM
64
Silvercrest Asset Management
New York
$4.37M +$1.44M +147,980 +48%
CM
65
CM Management
Florida
$4.34M
PAMU
66
Pictet Asset Management (UK)
United Kingdom
$3.88M +$206K +21,120 +6%
AllianceBernstein
67
AllianceBernstein
Tennessee
$3.66M -$36.1K -3,700 -1%
SCF
68
Sante Capital Fund
Texas
$3.54M +$3.58M +367,187 New
California State Teachers Retirement System (CalSTRS)
69
California State Teachers Retirement System (CalSTRS)
California
$3.49M -$259K -26,585 -7%
AA
70
ALPS Advisors
Colorado
$3.36M +$3.4M +348,441 New
State of Wisconsin Investment Board
71
State of Wisconsin Investment Board
Wisconsin
$3.34M
IC
72
Ikarian Capital
Texas
$3.29M
UBS AM
73
UBS AM
Illinois
$3.13M +$100K +10,288 +3%
PPA
74
Parametric Portfolio Associates
Washington
$3.08M +$266K +27,272 +9%
Hudson Bay Capital Management
75
Hudson Bay Capital Management
Connecticut
$3.04M +$3.07M +315,000 New

FOLD Hedge Fund Activity: Q2 2021 in Review

235 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2021, worth a combined $2.67B — down 2.5% from $2.74B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of FOLD and 32 opened new positions — a net loss of 22 holders — while 73 trimmed existing stakes and 85 added.

The largest buyer was Point72 Asset Management, adding an estimated $36M. The largest seller was Janus Henderson Group, cutting an estimated $39M.

  • 235 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2021, down from 259 in Q1 2021.
  • Funds reported $2.67B of Amicus Therapeutics stock for Q2 2021, down 2.5% quarter-over-quarter.
  • 32 funds opened new Amicus Therapeutics positions in Q2 2021 and 54 closed out, a net change of -22 holders.
  • The largest Amicus Therapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $36M added.
  • The largest Amicus Therapeutics seller in Q2 2021 was Janus Henderson Group, an estimated $39M sold.

Based on aggregated 13F filings for Q2 2021.